NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price & News $9.48 +0.19 (+2.05%) (As of 03:46 PM ET) Add Compare Share Share Today's Range$8.98▼$9.5150-Day Range$8.25▼$11.3552-Week Range$8.07▼$12.66Volume1.65 million shsAverage Volume2.32 million shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ironwood Pharmaceuticals MarketRank™ ForecastAnalyst Rating0.00 Rating ScoreUpside/Downside100.6% Upside$19.00 Price TargetShort InterestBearish10.17% of Float Sold ShortDividend StrengthN/ASustainability-2.94Upright™ Environmental ScoreNews Sentiment0.81Based on 7 Articles This WeekInsider TradingAcquiring Shares$300,119 Bought Last QuarterProj. Earnings Growth-50.78%From $1.28 to $0.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.67 out of 5 starsMedical Sector834th out of 961 stocksPharmaceutical Preparations Industry402nd out of 456 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Ironwood Pharmaceuticals has a forecasted upside of 100.6% from its current price of $9.47.Amount of Analyst CoverageIronwood Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.17% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently increased by 3.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIronwood Pharmaceuticals has received a 39.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Linaclotide" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ironwood Pharmaceuticals is -2.94. Previous Next 3.8 News and Social Media Coverage News SentimentIronwood Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ironwood Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $300,119.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.10% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to decrease by -50.78% in the coming year, from $1.28 to $0.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIronwood Pharmaceuticals has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ironwood Pharmaceuticals (NASDAQ:IRWD) StockIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More IRWD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRWD Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.1%September 20, 2023 | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Up After Insider Buying ActivitySeptember 25, 2023 | UNKNOWN (Ad)Top Wellness Nasdaq Stock for 2023Cutting-Edge Ai-Based Technology Is Set to Disrupt the Womens Wellness SpaceSeptember 19, 2023 | finance.yahoo.comIronwood Pharmaceuticals (IRWD): A Comprehensive Analysis of Its Market ValueSeptember 19, 2023 | finance.yahoo.comIronwood Pharmaceuticals Inc (IRWD): A Deep Dive into Its Performance PotentialSeptember 19, 2023 | americanbankingnews.comInsider Buying: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Purchases 36,072 Shares of StockSeptember 12, 2023 | finance.yahoo.comImplied Volatility Surging for Ironwood (IRWD) Stock OptionsAugust 26, 2023 | msn.comIronwood: Pipeline Progresses As FDA Approves LINZESSSeptember 25, 2023 | UNKNOWN (Ad)The Next Best AI Stock to Watch After NvidiaThis emerging NASDAQ company may be the best AI stock to watch in the AI boom. August 12, 2023 | finance.yahoo.comIs There An Opportunity With Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) 49% Undervaluation?August 8, 2023 | finance.yahoo.comIronwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass EstimatesAugust 8, 2023 | finance.yahoo.comIronwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue GuidanceAugust 8, 2023 | benzinga.comEarnings Preview For Ironwood PharmaceuticalsJuly 26, 2023 | finance.yahoo.comIronwood Pharmaceuticals to Host Second Quarter 2023 Investor Update CallJune 12, 2023 | markets.businessinsider.comIronwood Pharma's Pediatric Functional Constipation Treatment Gets FDA ApprovalJune 12, 2023 | msn.comFDA approves Ironwood's constipation drug Linzess for pediatric useJune 12, 2023 | finance.yahoo.comDown 7% in 2023, This Struggling Growth Stock Could Soon Make a TurnaroundJune 12, 2023 | finance.yahoo.comIronwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-OldJune 2, 2023 | seekingalpha.comIronwood Pharmaceuticals (IRWD) Presents At Life Sciences Conference -SlideshowMay 23, 2023 | msn.comIronwood Pharmaceuticals to Buy VectivBio for $1 Billion, Enhancing Gastrointestinal PortfolioMay 23, 2023 | msn.comPiper Sandler Maintains Ironwood Pharmaceuticals Inc - (IRWD) Overweight RecommendationMay 22, 2023 | reuters.comIronwood Pharma to acquire Swiss-based VectivBio in $1 bln dealMay 22, 2023 | seekingalpha.comIronwood falls 15% on deal to buy VectivBio for $17/share cashMay 22, 2023 | finance.yahoo.comWhy Ironwood Pharmaceuticals Stock Bumped Higher TodayMay 22, 2023 | markets.businessinsider.comIronwood Scoops Up Gastrointestinal Diseases Player For $1BMay 22, 2023 | msn.comIronwood Snaps Up VectivBio in GI PushMay 22, 2023 | markets.businessinsider.comWhy VectivBio Shares Are Surging MondaySee More Headlines Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Company Calendar Last Earnings8/08/2023Today9/25/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees219Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$19.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+103.4%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($6.04) Trailing P/E RatioN/A Forward P/E Ratio7.30 P/E GrowthN/ANet Income$175.07 million Net Margins-214.68% Pretax Margin-203.19% Return on Equity55.17% Return on Assets22.69% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales$410.60 million Price / Sales3.55 Cash Flow$1.15 per share Price / Cash Flow8.12 Book Value$4.24 per share Price / Book2.20Miscellaneous Outstanding Shares156,030,000Free Float135,589,000Market Cap$1.46 billion OptionableOptionable Beta0.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMs. Julie H. McHugh (Age 59)Exec. Chairman Comp: $95kMr. Thomas A. McCourt (Age 66)CEO & Director Comp: $1.42MMr. Sravan Kumar Emany (Age 45)Sr. VP, Principal Financial Officer & CFO Comp: $712.36kMr. John Minardo (Age 47)Sr. VP, Chief Legal Officer & Sec. Comp: $675.88kDr. Michael Shetzline M.D. (Age 64)Ph.D., Chief Medical Officer, Sr. VP and Head of Research & Drug Devel. Comp: $837.74kMr. Ronald Silver (Age 41)Corp. Controller & Principal Accounting Officer Mr. Marcel MoulaisonVP of Technical OperationsGreg MartiniVP of Strategic Fin. & Investor RelationsMs. Beth CalitriHead of Corp. Communications & Media RelationsMr. Mike NanfitoVP of Sales & Sales ExcellenceMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKGeronNASDAQ:GERNMannKindNASDAQ:MNKDDynavax TechnologiesNASDAQ:DVAXInnovivaNASDAQ:INVAView All CompetitorsInsiders & InstitutionsBarclays PLCBought 101,785 shares on 9/21/2023Ownership: 0.291%Sravan Kumar EmanyBought 36,072 shares on 9/15/2023Total: $300,119.04 ($8.32/share)Alberta Investment Management CorpSold 38,919 shares on 8/24/2023Ownership: 0.146%California State Teachers Retirement SystemSold 3,937 shares on 8/21/2023Ownership: 0.108%Teachers Retirement System of The State of KentuckyBought 2,341 shares on 8/21/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions IRWD Stock - Frequently Asked Questions What is Ironwood Pharmaceuticals' stock price forecast for 2023? 0 Wall Street analysts have issued 1 year price objectives for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price. View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts. How have IRWD shares performed in 2023? Ironwood Pharmaceuticals' stock was trading at $12.39 at the start of the year. Since then, IRWD stock has decreased by 24.6% and is now trading at $9.34. View the best growth stocks for 2023 here. When is Ironwood Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our IRWD earnings forecast. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. The biotechnology company had revenue of $107.38 million for the quarter, compared to the consensus estimate of $103.46 million. Ironwood Pharmaceuticals had a negative net margin of 214.68% and a positive trailing twelve-month return on equity of 55.17%. What ETFs hold Ironwood Pharmaceuticals' stock? ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Biotech ETF (XBI) and Pacer US Small Cap Cash Cows 100 ETF (CALF). What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings? Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $427.88 million. What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO? 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX). What is Ironwood Pharmaceuticals' stock symbol? Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD." Who are Ironwood Pharmaceuticals' major shareholders? Ironwood Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.61%), State Street Corp (7.10%), LSV Asset Management (4.94%), Dimensional Fund Advisors LP (3.61%), Renaissance Technologies LLC (3.42%) and Brown Capital Management LLC (2.41%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ironwood Pharmaceuticals' stock price today? One share of IRWD stock can currently be purchased for approximately $9.34. How much money does Ironwood Pharmaceuticals make? Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.46 billion and generates $410.60 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or ($6.04) on an earnings per share basis. How many employees does Ironwood Pharmaceuticals have? The company employs 219 workers across the globe. How can I contact Ironwood Pharmaceuticals? Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480. This page (NASDAQ:IRWD) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.